The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death

Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death

June 8, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Patients with OA on Low-Dose SoluMatrix Meloxicam Use Less Rescue Medication
Vivlodex, low-dose SoluMatrix meloxicam, capsules contain medication particles that are approximately 10 times smaller than in their original formulation, leading to increased surface area, faster dissolution and rapid absorption.1 In a Phase 3 clinical trial of patients with osteoarthritis (OA) and pain, patients who were treated with this meloxicam formulation used less rescue pain medication, regardless of time of day the treatment was taken, than patients who received placebo.2 Patients who took 10 mg Vivlodex-meloxicam had greater benefits, taking around half as much rescue medication (500 mg acetaminophen) as placebo-treated patients.

You Might Also Like
  • IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval
  • IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
  • Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
Also By This Author
  • Bisphosphonate Drug Holiday & Hip Fracture Risk

The data were presented at the 35th Annual Scientific Meeting of the American Pain Society in Austin by one of the poster co-authors, Alan J. Kivitz, MD, CPI, president of the Altoona Center for Clinical Research, Duncansville, Pa., and president of the Altoona Arthritis and Osteoporosis Center, also in Duncansville.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This was a Phase 3, 12-week, double-blind, multicenter, placebo-controlled study that enrolled 403 adults who were chronic non-steroidal anti-inflammatory and/or acetaminophen users with knee or hip OA. Patients were randomized to receive either once daily Vivlodex (either 5 or 10 mg) or placebo. Acetaminophen rescue medication was allowed every four to six hours as needed, which was provided in bottles equipped with a medication event monitoring system (MEMS) cap that recorded bottle openings. Pill counts were also conducted. By using MEMS to capture use of rescue medication, this study was able to obtain insight as to the time of day rescue medication was needed. These types of data usually cannot be obtained unless patients are observed at all times, which increases clinical trial manpower and costs.

FDA Warning: Off-Label Use of Ketoconazole Results in Death
The U.S. Food and Drug Administration (FDA) is reminding healthcare professionals not to prescribe oral ketoconazole to treat skin and nail fungal infections.3 Patients using oral ketoconazole for treating onychomycosis and fungal skin infections run the risk of serious hepatotoxicity, adrenal gland problems and harmful drug interactions. The benefits do not outweigh the risks in treating these conditions, which are not approved uses for this product. This indication was removed from the ketoconazole label in 2013.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

An FDA safety review has determined that oral ketoconazole continues to be prescribed to treat skin and nail fungal infections. Subsequent to the 2013 label change, at least one patient death due to liver failure has been associated with its use and reported to the FDA. Healthcare professionals should reserve oral ketoconazole tablets to treat only serious fungal infections when no other antifungal therapies are available.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Drug Updates, Safety Tagged With: Drug Safety, FDA, Food and Drug Administration, ketoconazole, meloxicam, Osteoarthritis, Pain, safety warning, SoluMatrix

You Might Also Like:
  • IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval
  • IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
  • Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
  • Safety Risk with Higher Dose Tofacitnib

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.